In last trading session, Lineage Cell Therapeutics, Inc. (NYSE:LCTX) saw 1,987,433 shares changing hands with its beta currently measuring 2.12. Company’s recent per share price level of $1.05 trading at $0.11 or 11.65% at ring of the bell on the day assigns it a market valuation of $157.48 Million. That closing price of LCTX’s stock is at a discount of -59.05% from its 52-week high price of $1.67 and is indicating a premium of 49.52% from its 52-week low price of $0.53. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 448.15 Million shares which gives us an average trading volume of 970.87 Million if we extend that period to 3-months.
For Lineage Cell Therapeutics, Inc. (LCTX), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.2. Splitting up the data highlights that, out of 3 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.04 in the current quarter.
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) trade information
Upright in the green today for gaining 11.65%, in the last five days LCTX remained trading in the green while hitting it’s week-highest on Wednesday, Sep 16 when the stock touched $1.08 price level, adding 2.78% to its value on the day. Lineage Cell Therapeutics, Inc.’s shares saw a change of 17.98% in year-to-date performance and have moved 15.38% in past 5-day. Lineage Cell Therapeutics, Inc. (NYSE:LCTX) showed a performance of 14.13% in past 30-days. Number of shares sold short was 6.24 Million shares which calculate 0.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $5 to the stock, which implies a rise of 376.19% to its current value. Analysts have been projecting $3 as a low price target for the stock while placing it at a high target of $7. It follows that stock’s current price would jump +566.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of 185.71% for stock’s current value.
Lineage Cell Therapeutics, Inc. (LCTX) estimates and forecasts
Statistics highlight that Lineage Cell Therapeutics, Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added +74.97% of value to its shares in past 6 months, showing an annual growth rate of 137.5% while that of industry is 13.7. Apart from that, the company came raising its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to increase by 63.6% in the current quarter and calculating -33.3% decline in the next quarter. This year revenue growth is estimated to drop -38.5% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $430Million for the same. And 2 analysts are in estimates of company making revenue of $420Million in the next quarter that will end in December 01, 2020. Company posted $567Million and $1.24 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -24.2% while estimating it to be -66.2% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 31.9% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 77.8% while estimates for its earnings growth in next 5 years are of 0%